Literature DB >> 26915339

Assisted reproductive technologies for male subfertility.

Maartje Cissen1, Alexandra Bensdorp, Ben J Cohlen, Sjoerd Repping, Jan Peter de Bruin, Madelon van Wely.   

Abstract

BACKGROUND: Intra-uterine insemination (IUI), in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) are frequently used fertility treatments for couples with male subfertility. The use of these treatments has been subject of discussion. Knowledge on the effectiveness of fertility treatments for male subfertility with different grades of severity is limited. Possibly, couples are exposed to unnecessary or ineffective treatments on a large scale.
OBJECTIVES: To evaluate the effectiveness and safety of different fertility treatments (expectant management, timed intercourse (TI), IUI, IVF and ICSI) for couples whose subfertility appears to be due to abnormal sperm parameters. SEARCH
METHODS: We searched for all publications that described randomised controlled trials (RCTs) of the treatment for male subfertility. We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO and the National Research Register from inception to 14 April 2015, and web-based trial registers from January 1985 to April 2015. We applied no language restrictions. We checked all references in the identified trials and background papers and contacted authors to identify relevant published and unpublished data. SELECTION CRITERIA: We included RCTs comparing different treatment options for male subfertility. These were expectant management, TI (with or without ovarian hyperstimulation (OH)), IUI (with or without OH), IVF and ICSI. We included only couples with abnormal sperm parameters. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies, extracted data and assessed risk of bias. They resolved disagreements by discussion with the rest of the review authors. We performed statistical analyses in accordance with the guidelines for statistical analysis developed by The Cochrane Collaboration. The quality of the evidence was rated using the GRADE methods. Primary outcomes were live birth and ovarian hyperstimulation syndrome (OHSS) per couple randomised. MAIN
RESULTS: The review included 10 RCTs (757 couples). The quality of the evidence was low or very low for all comparisons. The main limitations in the evidence were failure to describe study methods, serious imprecision and inconsistency. IUI versus TI (five RCTs)Two RCTs compared IUI with TI in natural cycles. There were no data on live birth or OHSS. We found no evidence of a difference in pregnancy rates (2 RCTs, 62 couples: odds ratio (OR) 4.57, 95% confidence interval (CI) 0.21 to 102, very low quality evidence; there were no events in one of the studies).Three RCTs compared IUI with TI both in cycles with OH. We found no evidence of a difference in live birth rates (1 RCT, 81 couples: OR 0.89, 95% CI 0.30 to 2.59; low quality evidence) or pregnancy rates (3 RCTs, 202 couples: OR 1.51, 95% CI 0.74 to 3.07; I(2) = 11%, very low quality evidence). One RCT reported data on OHSS. None of the 62 women had OHSS.One RCT compared IUI in cycles with OH with TI in natural cycles. We found no evidence of a difference in live birth rates (1 RCT, 44 couples: OR 3.14, 95% CI 0.12 to 81.35; very low quality evidence). Data on OHSS were not available. IUI in cycles with OH versus IUI in natural cycles (five RCTs)We found no evidence of a difference in live birth rates (3 RCTs, 346 couples: OR 1.34, 95% CI 0.77 to 2.33; I(2) = 0%, very low quality evidence) and pregnancy rates (4 RCTs, 399 couples: OR 1.68, 95% CI 1.00 to 2.82; I(2) = 0%, very low quality evidence). There were no data on OHSS. IVF versus IUI in natural cycles or cycles with OH (two RCTs)We found no evidence of a difference in live birth rates between IVF versus IUI in natural cycles (1 RCT, 53 couples: OR 0.77, 95% CI 0.25 to 2.35; low quality evidence) or IVF versus IUI in cycles with OH (2 RCTs, 86 couples: OR 1.03, 95% CI 0.43 to 2.45; I(2) = 0%, very low quality evidence). One RCT reported data on OHSS. None of the women had OHSS.Overall, we found no evidence of a difference between any of the groups in rates of live birth, pregnancy or adverse events (multiple pregnancy, miscarriage). However, most of the evidence was very low quality.There were no studies on IUI in natural cycles versus TI in stimulated cycles, IVF versus TI, ICSI versus TI, ICSI versus IUI (with OH) or ICSI versus IVF. AUTHORS'
CONCLUSIONS: We found insufficient evidence to determine whether there was any difference in safety and effectiveness between different treatments for male subfertility. More research is needed.

Entities:  

Mesh:

Year:  2016        PMID: 26915339     DOI: 10.1002/14651858.CD000360.pub5

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  10 in total

1.  Protective effect of resveratrol on spermatozoa function in male infertility induced by excess weight and obesity.

Authors:  Xiangrong Cui; Xuan Jing; Xueqing Wu; Meiqin Yan
Journal:  Mol Med Rep       Date:  2016-10-12       Impact factor: 2.952

2.  The effectiveness of Korean medicine treatment in male patients with infertility: a study protocol for a prospective observational pilot study.

Authors:  Kwan-Ii Kim; Junyoung Jo
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

3.  Drawbacks of the current practice.

Authors:  Ashok Agarwal; Chak-Lam Cho; Ahmad Majzoub; Sandro C Esteves
Journal:  Transl Androl Urol       Date:  2017-09

4.  Stem Cells as a Resource for Treatment of Infertility-related Diseases.

Authors:  Jing Wang; Chi Liu; Masayuki Fujino; Guoqing Tong; Qinxiu Zhang; Xiao-Kang Li; Hua Yan
Journal:  Curr Mol Med       Date:  2019       Impact factor: 2.222

5.  Comparative Analysis of Surgically Retrieved Sperms in Cases of Obstructive and Nonobstructive Azoospermia Treated for Infertility.

Authors:  Deepa Talreja; Chirag Gupta; Hrishikesh Pai; Nandita Palshetkar; Rupin Shah
Journal:  J Hum Reprod Sci       Date:  2020-10-27

6.  Sperm selection with hyaluronic acid improved live birth outcomes among older couples and was connected to sperm DNA quality, potentially affecting all treatment outcomes.

Authors:  Robert West; Arri Coomarasamy; Lorraine Frew; Rachel Hutton; Jackson Kirkman-Brown; Martin Lawlor; Sheena Lewis; Riitta Partanen; Alex Payne-Dwyer; Claudia Román-Montañana; Forough Torabi; Sofia Tsagdi; David Miller
Journal:  Hum Reprod       Date:  2022-05-30       Impact factor: 6.353

Review 7.  Contemporary Use of ICSI and Epigenetic Risks to Future Generations.

Authors:  Romualdo Sciorio; Sandro C Esteves
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

Review 8.  Diagnosis and Management of Infertility: A Review.

Authors:  Sandra Ann Carson; Amanda N Kallen
Journal:  JAMA       Date:  2021-07-06       Impact factor: 157.335

9.  The Mechanism of Zinc Sulfate in Improving Fertility in Obese Rats Analyzed by Sperm Proteomic Analysis.

Authors:  Jing Ma; Ruiyu Han; Yuanlong Li; Tong Cui; Shusong Wang
Journal:  Biomed Res Int       Date:  2020-05-04       Impact factor: 3.411

10.  Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles.

Authors:  Gulam Bahadur; Roy Homburg; Judith E Bosmans; Judith A F Huirne; Peter Hinstridge; Kanna Jayaprakasan; Paul Racich; Rakib Alam; Ioannis Karapanos; Afeeza Illahibuccus; Ansam Al-Habib; Eric Jauniaux
Journal:  BMJ Open       Date:  2020-03-16       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.